Cargando…
Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling
BACKGROUND: Afatinib is mainly used to treat advanced non-small cell lung cancer, but its therapeutic effect on hepatocellular carcinoma is still unclear. METHODS: Over 800 drugs were screened by CCK8 technology and afatinib was found to have a significant inhibitory effect on liver cancer cells. Th...
Autores principales: | Yu, Chao, Zhang, Xinyi, Wang, Min, Xu, Gaoxin, Zhao, Siqi, Feng, Yongheng, Pan, Chao, Yang, Weijun, Zhou, Jin, Shang, Longcheng, Ma, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266343/ https://www.ncbi.nlm.nih.gov/pubmed/37324014 http://dx.doi.org/10.3389/fonc.2023.1198118 |
Ejemplares similares
-
Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
por: Kong, Yuehong, et al.
Publicado: (2021) -
Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021) -
Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022) -
Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
por: Yang, Yuanyuan, et al.
Publicado: (2022) -
Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma
por: Xu, Liqin, et al.
Publicado: (2022)